Quanterix has appointed Dr. Yuri Fesko as Chief Medical Officer to strengthen its clinical and medical leadership. The company announced the appointment as it prepares to expand its diagnostics business. Quanterix Corporation (Nasdaq: QTRX) is a global leader in precision biomarker science. In his new role, Dr. Fesko will provide medical and clinical leadership across the company.
He will work closely with the Diagnostics, Scientific, R&D, Regulatory, and Commercial teams. Together, these teams will advance Quanterix’s technologies and clinical applications. The appointment comes as Quanterix prepares for the broader market launch of its Lucent AD® Complete five biomarker test. The test is designed for Alzheimer’s Disease. Dr. Fesko will also support Quanterix as it advances its diagnostics strategy. His experience is expected to strengthen the company’s clinical development and regulatory efforts.
“As we prepare for the broader market launch of our Lucent AD® Complete five biomarker test for Alzheimer’s Disease, we welcome Dr. Yuri Fesko to Quanterix in an important new role to support our efforts to efficiently scale our expansion in diagnostics,” said Everett Cunningham, President & CEO of Quanterix. “Yuri’s deep experience in clinical affairs at a large, well-known diagnostics company, especially his expertise in precision medicine, will provide us with an exceptional resource as we accelerate the launch of our industry-leading Lucent AD Complete test and advance the IVD filing for our HD-X instrument. His ability to work at the intersection of medicine, diagnostics, analytics, and business strategy will be especially valuable as we continue to build our Diagnostics business and expand the clinical impact of Quanterix’s technologies.”
Dr. Fesko Brings Diagnostics Leadership
Before joining Quanterix, Dr. Fesko served as Chief Medical Officer at Quest Diagnostics. He oversaw Medical Affairs, Clinical Development, Analytics, and Public Health. He also provided medical and analytical leadership across the organization. In addition, he served as the medical lead supporting Quality and Regulatory functions. His responsibilities also included senior-level medical leadership for pathology and dermatopathology. This experience exposes him extensively to clinical and diagnostic operations.
Dr. Fesko has spent his career mastering precision medicine strategies. He spent his life developing and implementing advanced diagnostic solutions. He has particular experience across oncology, metabolic disease and neurology and consumer health. These are areas that fit in with the growing role of precision diagnostics in modern health care. Dr. Fesko has also worked extensively with health systems. His professional experience includes collaborations with pharmaceutical and biotechnology companies.
Furthermore, he has partnered with physician organizations to integrate precision diagnostics into clinical practice. He has also supported the use of these technologies in clinical trials. His background includes significant experience with FDA submissions and clinical development. He has also worked on companion diagnostic strategies and reimbursement planning. These capabilities will support Quanterix as it advances its diagnostic technologies. They will also help the company strengthen its clinical and regulatory programs.
Quanterix Advances Precision Diagnostics
Dr. Fesko’s appointment comes during an important period for Quanterix. The company continues to expand its position in precision biomarker science and diagnostics. His clinical background will support the company’s efforts to advance new diagnostic applications. It will also help connect medical strategy with commercial and scientific priorities. The upcoming Lucent AD® Complete launch represents an important step for Quanterix. The five biomarker test is designed to support Alzheimer’s Disease diagnostics.
At the same time, Quanterix continues advancing the IVD filing for its HD-X instrument. Dr. Fesko’s experience will support these efforts across clinical and regulatory functions. His previous leadership at Quest Diagnostics also brings experience from a major diagnostics organization. That background includes medical affairs, analytics, clinical development, and public health. Moreover, his precision medicine expertise covers several important areas of healthcare. These include oncology, neurology, metabolic disease, and consumer health.
Quanterix expects his experience to contribute to its broader Diagnostics business. The company is also focused on expanding the clinical impact of its technologies. Dr. Fesko holds Bachelor’s and Doctor of Medicine degrees from Case Western Reserve University. He also completed a Fellowship at University Hospitals of Cleveland. He is board-certified in Internal Medicine, Hematology, and Medical Oncology. Dr. Fesko will be based at Quanterix’s headquarters in Billerica, Massachusetts.
His appointment adds medical leadership to Quanterix as it moves forward with its diagnostics strategy. It also underscores the company’s ongoing focus on precision medicine and biomarker-based testing. “The addition of Dr. Fesko to the leadership team further enhances Quanterix’s clinical expertise. The company will continue to develop technologies designed to expand precision diagnostics and its impact on patient care.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
